Skip to main content
. 2022 Mar 29;2(2):139–153. doi: 10.1016/j.jacasi.2022.02.004

Central Illustration.

Central Illustration

DAPA-HF in Asia

Effect estimates are displayed as HRs and 95% CIs were estimated with the use of Cox regression models, stratified according to diabetes status, with a history of hospitalization for heart failure and treatment group assignment as explanatory variables. “All trial patients” refers to all 4,744 patients randomized in 20 countries worldwide. The interaction P value is from a test for interaction between region (Asia/non-Asia) and treatment effect. BMI = body mass index; DAPA-HF = Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association.